Subvert tradition! Mutations at the same point can have different effects

According to a new study by the University of Eastern Finland, the effects of KRAS mutations vary widely among many different tumors. Different mutations of the same amino acids on KRAS proteins have different effects on protein function, so treatment and drug development for different KRAS mutations may require different ways. The new study was published recently in PLOS Computational Biology.
mutations in proteins in the human body are important factors leading to cancer, one of the most important of which is KRAS, whose mutations play a key role in the development of pancreatic cancer. Mutations in KRAS protein 12 amino acids- glycine may convert glycine into six other amino acids, all of which insulate the protein. This causes cells to grow out of control, eventually forming tumor tissue.
past studies have suggested that since all six mutations occur in the same location, the effects should be the same. But that's not the case, as the new study found, with different types of mutations occurring in different tissues. This means that different mutations may have different effects on protein function.
the differences in the effects of different mutations on protein function with the help of computer-simulated molecular dynamics methods. The results show that different mutations have different effects on the dynamics of proteins, resulting in different effects on protein function. These differences may partly explain why different tissues have different probabilities of different mutations.
study is the first to reveal the effects of different mutations at the same location on the level function of kras proteins. Mutations in kraS protein 12 amino acid glycine are common in rectal, lung, and pancreatic cancers, especially in pancreatic catheter cancer. Pancreatic catheter cancer is one of the worst prognosis cancers and there is no effective treatment.
findings have deepened our understanding of the effects of different mutations. In the future, this will help us develop and select new drugs that target the function of the mutant KRAS protein. (Bio Valley)